HUGON Jacques
Biocanvas Paris
France
PKR and danger molecules in Alzheimers disease
ANR
787,910
01/01/2013
4.0
Alzheimer's disease & other dementias
Alzheimers disease (AD) is a neurodegenerative disease leading to cognitive deficits which is becoming a major public health issue because of population aging and the lack of effective treatment. Neuropathological lesions include senile plaques made of accumulated ß-amyloid (Aß) peptide, neurofibrillary tangles containing hyperphosphorylated tau protein, and synaptic
and neuronal losses. The amyloid cascade hypothesis implies that the Aß peptide is neurotoxic and could be responsible for neuronal degeneration in AD brains. Formation of the Aß peptide results from the cleavage of the amyloid precursor protein (APP) at specific sites. The enzymes involved are the ß-site APP-cleaving enzyme 1 (BACE1) and ?-secretases. BACE1 levels are increased in the brains of AD patients, providing a possible explanation for Aß accumulation. PKR (double stranded RNA-dependent protein kinase) is a pro-apoptotic, neurotoxic and pro-inflammatory kinase initially identified in the context of antiviral responses. It blocks protein synthesis by phosphorylating eukaryotic initiation factor 2a (eIF2a). We have discovered that PKR is activated in degenerating neurons of AD brains and in response to Aß in cells in culture. In addition, we have shown that PKR can contol tau phosphorylation and the levels of BACE1.PKR can thus exert multiple neurotoxic effects. PKR activation can be triggered by a number of metabolic or inflammatory stresses that are known to favor the occurrence of AD. Danger molecules (like S100a8,S100a9 or biglycan) are released by activated macrophages or lesioned tissues and can activate innate immunity and PKR. We propose that PKR activation and danger molcules may contribute significantly to the pathogenesis of AD by amplifying the production of Aß and initiating and/or potentiating neurotoxic events. Thus activated PKR may be a useful early biomarker of the disease as well as a promising novel therapeutic target. The general aim of this project is to test these hypotheses and assess the role of PKR in AD. The proposed tasks are to: – Determine if the neurotixicity of PKR in cultures can be mediated by danger molecules released by activated microglial cells . – Examine whether deficit in PKR slows down the evolution of toxic and genetic mouse models of AD using neuropathological and cognitive/behavioral readouts. Evaluate the interest of PKR and danger molecules as early biomarkers in MCI od AD
patients. This project will be carried out in 4 laboratories each with an established expertise in complementary fields. It combines clinical and basic research, including in vitro experiments in neurons in culture, experiments in several genetic mouse
models, and study of human brain samples and of blood and cerebrospinal fluid (CSF) samples from AD and MCI (mild cognitive impairment) patients and controls. The expected output is a better understanding of AD pathogenesis, an evaluation of potential novel early biomarkers, and the possible identification of a novel target for pharmacological treatment of AD.